• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Complete Financial Solutions Inc
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

1.650 -0.090 (-5.17%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 58,525
Open 1.700
Bid (Size) 1.600 (800)
Ask (Size) 1.730 (200)
Prev. Close 1.740
Today's Range 1.600 - 1.770
52wk Range 1.460 - 22.20
Shares Outstanding 11,813,610
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
October 14, 2026
-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
October 08, 2026
Continued participation underscores commitment to expanding options for patients referred to fertility centers under the care of reproductive endocrinologists 
From Femasys Inc.
Via GlobeNewswire

Performance

52-Week Range 92.6% below 52-week high
1.650
1.4652W Low 22.2052W High
1 Week 18.3% below 1-week high
1.461W Low 2.021W High

Femasys Inc. - Common Stock (FEMY) traded between $1.46 and $22.20 over the past 52 weeks and last traded at $1.65, 92.6% below its 52-week high. Over the past week it ranged between $1.46 and $2.02.

Past 12 Months
-5.7%
-35.3%
-49.5%
-80.6%
-87.0%
-88.3%
1W -$0.10
1M -$0.90
3M -$1.62
6M -$6.84
YTD -$11.08
1Y -$12.41

FEMY was -88.3% over the past year, -80.6% over six months, -87.0% year to date, -5.7% in the last week.

12 Months vs Market
FEMY
-88.3%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months FEMY returned -88.3% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.08× 3-mo avg
Today 58,525 3-mo avg 728.1K
1W
100.0K
1M
96.7K
3M
728.1K
6M
400.6K
YTD
266.5K
1Y
268.4K

FEMY most recently traded 58,525 shares against a 3-month average daily volume of 728.1K.

More News

Read More
News headline image
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
September 15, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
September 09, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
August 26, 2026
From Femasys Inc.
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
August 19, 2026
Via Chartmill
News headline image
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
August 19, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
August 14, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
August 12, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
August 07, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Regains Compliance with Nasdaq Listing Requirements
June 24, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
May 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
Wondering what's happening in today's after-hours session? ↗
May 25, 2026
Via Chartmill
Get insights into the top gainers and losers of Friday's after-hours session. ↗
May 22, 2026
Via Chartmill
News headline image
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
May 13, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
May 08, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
May 05, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
April 22, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
April 16, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
April 01, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
March 31, 2026
From Femasys Inc.
Via GlobeNewswire
Traders are paying attention to the gapping stocks in Monday's session. ↗
March 30, 2026
Via Chartmill
News headline image
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
March 18, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
March 10, 2026
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
February 26, 2026
From Femasys Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Femasys Inc. - Common Stock publicly traded?
Yes, Femasys Inc. - Common Stock is publicly traded.
What exchange does Femasys Inc. - Common Stock trade on?
Femasys Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Femasys Inc. - Common Stock?
The ticker symbol for Femasys Inc. - Common Stock is FEMY on the Nasdaq Stock Market
What is the current price of Femasys Inc. - Common Stock?
The current price of Femasys Inc. - Common Stock is 1.650
When was Femasys Inc. - Common Stock last traded?
The last trade of Femasys Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Femasys Inc. - Common Stock?
The market capitalization of Femasys Inc. - Common Stock is 19.49M
How many shares of Femasys Inc. - Common Stock are outstanding?
Femasys Inc. - Common Stock has 19M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap